SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction.
Stem cell transplantation at the time of acute myocardial infarction (AMI) improves cardiac function. Whether the improved cardiac function results from regeneration of cardiac myocytes, modulation of remodeling, or preservation of injured tissue through paracrine mechanisms is actively debated. Because no specific stem cell population has been shown to be optimal, we investigated whether the benefit of stem cell transplantation could be attributed to a trophic effect on injured myocardium. Mesenchymal stem cells secrete SDF-1 and the interaction of SDF-1 with its receptor, CXCR4, increases survival of progenitor cells. Therefore, we compared the effects of MSC and MSC engineered to overexpress SDF-1 on cardiac function after AMI. Tail vein infusion of syngeneic MSC and MSC:SDF-1 1 day after AMI in the Lewis rat led to improved cardiac function by echocardiography by 70.7% and 238.8%, respectively, compared with saline controls 5 wk later. The beneficial effects of MSC and MSC:SDF-1 transplantation were mediated primarily through preservation, not regeneration of cardiac myocytes within the infarct zone. The direct effect of SDF-1 on cardiac myocytes was due to the observation that, between 24 and 48 h after AMI, SDF-1-expressing MSC increased cardiac myocyte survival, vascular density (18.2+/-4.0 vs. 7.6+/-2.3 vessels/mm2, P<0.01; SDF-1:MSC vs. MSC), and cardiac myosin-positive area (MSC: 49.5%; mSC:SDF-1: 162.1%) within the infarct zone. There was no evidence of cardiac regeneration by the infused MSC or endogenous cardiac stem cells based on lack of evidence for cardiac myocytes being derived from replicating cells. These results indicate that stem cell transplantation may have significant beneficial effects on injured organ function independent of tissue regeneration and identify SDF-1:CXCR4 binding as a novel target for myocardial preservation.
Zhang
Ming
M
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, USA.
Mal
Niladri
N
Kiedrowski
Matthew
M
Chacko
Matthews
M
Askari
Arman T
AT
Popovic
Zoran B
ZB
Koc
Omer N
ON
Penn
Marc S
MS
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002470:Cell Survival; D002478:Cells, Cultured; D054377:Chemokine CXCL12 / Q000235:genetics / Q000378:metabolism*; D005456:Fluorescent Dyes / Q000378:metabolism; D000860:Hypoxia; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000502:physiology*; D009203:Myocardial Infarction / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D017202:Myocardial Ischemia; D032383:Myocytes, Cardiac / Q000166:cytology / Q000378:metabolism*; D051381:Rats; D011917:Rats, Inbred Lew; D019718:Receptors, CXCR4 / Q000235:genetics / Q000378:metabolism; D033581:Stem Cell Transplantation
D015415:Biomarkers; D054377:Chemokine CXCL12; C486264:Cxcr4 protein, rat; D005456:Fluorescent Dyes; D019718:Receptors, CXCR4